Vest Financial LLC Has $2.28 Million Holdings in Gilead Sciences, Inc. $GILD

Vest Financial LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 41.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,491 shares of the biopharmaceutical company’s stock after purchasing an additional 6,019 shares during the quarter. Vest Financial LLC’s holdings in Gilead Sciences were worth $2,275,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Forvis Mazars Wealth Advisors LLC bought a new position in shares of Gilead Sciences during the third quarter worth approximately $243,000. McAdam LLC increased its stake in Gilead Sciences by 7.6% during the 3rd quarter. McAdam LLC now owns 25,415 shares of the biopharmaceutical company’s stock worth $2,821,000 after acquiring an additional 1,787 shares during the period. Triasima Portfolio Management inc. increased its stake in Gilead Sciences by 12.8% during the 3rd quarter. Triasima Portfolio Management inc. now owns 39,111 shares of the biopharmaceutical company’s stock worth $4,341,000 after acquiring an additional 4,445 shares during the period. Sage Mountain Advisors LLC raised its holdings in Gilead Sciences by 10.9% in the 3rd quarter. Sage Mountain Advisors LLC now owns 8,604 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 847 shares in the last quarter. Finally, Inscription Capital LLC lifted its position in shares of Gilead Sciences by 35.7% during the 3rd quarter. Inscription Capital LLC now owns 4,656 shares of the biopharmaceutical company’s stock valued at $517,000 after acquiring an additional 1,224 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 141,757 shares of company stock valued at $17,569,112. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $131.14 on Friday. Gilead Sciences, Inc. has a one year low of $92.21 and a one year high of $133.10. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company has a market cap of $162.70 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 0.68 and a beta of 0.33. The firm has a 50 day simple moving average of $123.76 and a 200 day simple moving average of $118.46.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.4%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GILD shares. Mizuho raised their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Scotiabank began coverage on shares of Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective on the stock. Morgan Stanley dropped their target price on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, January 13th. Citigroup upped their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, UBS Group reissued a “buy” rating on shares of Gilead Sciences in a research note on Thursday, January 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.